Drug Trial Radar · NCT07752264
A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Aug 15, 2026
Primary completion
Aug 15, 2030
Study completion Aug 15, 2043
Sponsor
- Lead sponsor
- Nanjing IASO Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm Phase I/II clinical study to evaluate the efficacy and safety of Eque-cel Injection in patients with refractory immune-mediated necrotizing myopathy.
Conditions
- Refractory Immune-mediated Necrotizing Myopathy
Interventions
Equecabtagene Autoleucel Injection (Eque-cel)Drug
Eque-cel is a personalized, BCMA-targeted gene-modified autologous T-cell immunotherapy product capable of recognizing and eliminating both malignant and normal cells expressing BCMA. The CAR specifically identifies BCMA via a fully human single-chain variable fragment (scFv) with low immunogenicity, activates, proliferates, secretes cytokines, and kills target cells through the CD3ζ domain, while enhancing CAR-T expansion and persistence via 4-1BB costimulation signaling. Eque-cel demonstrates high affinity for the BCMA antigen both in vitro and in vivo, as well as efficient killing of antigen-loaded cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Safety endpoint - Adverse Events (AEs)Time frame: up to 2 years from Eque-cel Injection infusion
- Phase I: Safety endpoint-incidence of Dose-limiting toxicity (DLT)Time frame: Time Frame: up to 28 days from Eque-cel Injection infusion
- Phase II: Efficacy endpoint- TIS responseTime frame: up to the 2 years after Eque-cel Injection infusion
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Huashan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.